Tislelizumab
Perioperative/Postoperative Complications
Cambridge University Hospitals NHS Foundation Trustmonoclonal_antibodyPhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Perioperative/Postoperative Complications cohort.
View all 14 →
Same molecule, other indications
Tislelizumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →